Home Cart Sign in  
Chemical Structure| 1085412-37-8 Chemical Structure| 1085412-37-8

Structure of Pyridostatin
CAS No.: 1085412-37-8

Chemical Structure| 1085412-37-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Pyridostatin is a G-quadruplex-interacting drug which can promote growth arrest in human cancer cells by inducing replication- and transcription-dependent DNA damage.

Synonyms: RR82

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Pyridostatin

CAS No. :1085412-37-8
Formula : C31H32N8O5
M.W : 596.64
SMILES Code : O=C(C1=CC(OCCN)=CC(C(NC2=NC3=C(C(OCCN)=C2)C=CC=C3)=O)=N1)NC4=CC(OCCN)=C5C=CC=CC5=N4
Synonyms :
RR82
MDL No. :MFCD25976689

Safety of Pyridostatin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Pyridostatin

DNA

Isoform Comparison

Biological Activity

Description
Pyridostatin stabilizes G-quadruplex DNA structures with a dissociation constant (Kd) of 490 nM, leading to growth arrest in human cancer cells by causing DNA damage dependent on both replication and transcription. It specifically targets the Src proto-oncogene, leading to reduced SRC protein levels and decreased SRC-dependent cell movement in human breast cancer cells[1][2].

In Vitro:

Cell Line
Concentration Treated Time Description References
Astrocytes 2 µM Overnight PDS downregulates Atg7 mRNA and ATG7 protein levels Autophagy. 2020 Dec;16(12):2252-2259
Neurons 2 µM Overnight PDS downregulates Atg7 expression and reduces autophagy Autophagy. 2020 Dec;16(12):2252-2259
IPAM cells 10 µM 12 hours To evaluate the stabilizing effect of PDS on the PRRSV-G4 structure and its impact on viral replication. Results showed that PDS treatment significantly inhibited PRRSV replication. Nucleic Acids Res. 2023 Oct 27;51(19):10752-10767
HeLa cells 20 µM 12 hours To investigate the effect of Pyridostatin on the interaction between G3BP1 and rG4 structures, results showed that Pyridostatin could displace G3BP1 from mRNA, with the most pronounced effects observed in the 3'-untranslated regions (3'-UTR) of mRNAs. Nucleic Acids Res. 2021 Nov 8;49(19):11323-11336
HEK293T cells 20 µM 12 hours To investigate the effect of Pyridostatin on the interaction between G3BP1 and rG4 structures, results showed that Pyridostatin could displace G3BP1 from mRNA, with the most pronounced effects observed in the 3'-untranslated regions (3'-UTR) of mRNAs. Nucleic Acids Res. 2021 Nov 8;49(19):11323-11336
U2OS human osteosarcoma cell line 1 µM 12 hours Pyridostatin-α formed nuclear foci in cells, co-localizing with hPif1. Nat Chem Biol. 2012 Feb 5;8(3):301-10
DLD1 BRCA2−/− 2 µM 16 hours Evaluate the effect of Pyridostatin on DNA damage in BRCA2−/− cells, showing significant increase in DNA breaks, repaired after 72 hours EMBO Mol Med. 2022 Mar 7;14(3):e14501
DLD1 BRCA2+/+ 2 µM 16 hours Evaluate the effect of Pyridostatin on DNA damage in BRCA2+/+ cells, showing no significant increase in DNA breaks EMBO Mol Med. 2022 Mar 7;14(3):e14501
RPE-1 BRCA1−/− 10 µM 2 days Evaluate DNA damage and immune responses induced by Pyridostatin in BRCA1-deficient cells, showing increased KAP1 Ser824 and IRF3 Ser386 phosphorylation EMBO Mol Med. 2022 Mar 7;14(3):e14501
A549 10 µM 2 hours H2O2 treatment, 4 hours recovery To study the effect of PDS (rG4 structure stabilizer) on FEN1 expression, results showed that PDS pretreatment upregulated FEN1 expression. Antioxidants (Basel). 2023 Jan 26;12(2):276
HeLa cancer cells 10 µM 24 hours Applied mass spectrometry (MS) based quantitative proteomics to profile the protein expression of HeLa cells subjected to PDS treatment. Results showed that PDS significantly downregulated 22 proteins but upregulated 16 proteins. Nucleic Acids Res. 2022 Apr 8;50(6):3070-3082
PK-15 CD163 cells 10 µM 24 hours To investigate the effect of PDS on PRRSV replication. Results showed that PDS treatment significantly reduced viral RNA levels and protein expression. Nucleic Acids Res. 2023 Oct 27;51(19):10752-10767
Murine B16-F10 melanoma cells 10 µM 24 hours To study the immune gene activation effect of PDS in murine melanoma cells, showing PDS activated STING translocation and immune gene expression in wild-type B16 cells but not in STING knockout cells. Nucleic Acids Res. 2021 Jul 9;49(12):6673-6686
Human MRC5 normal lung cells 10 µM 24 hours To determine the immune gene activation effect of PDS in normal cells, showing only IFNB gene was activated and secreted IFNB protein levels were much lower than in MCF-7 cells. Nucleic Acids Res. 2021 Jul 9;49(12):6673-6686
Human MCF-7 breast cancer cells 10 µM 24 hours To measure the cytotoxic potency of PDS, showing its IC50 is 81.6 μM. At a lower dose of 10 μM, PDS only slightly affected MCF-7 cell growth but increased the levels of G4 and γH2AX (phosphorylated S139 H2AX histone) foci. Nucleic Acids Res. 2021 Jul 9;49(12):6673-6686
HEK293T cells 5 µM 24 hours To evaluate the effect of the PA-PDS conjugate ligand on the regulation of gene expression in the hTERT 5-12 DNA promoter region. Results showed that the PA-PDS conjugate ligand significantly reduced Renilla luciferase activity more than PA or PDS alone. Nucleic Acids Res. 2024 Oct 14;52(18):10775-10787
HepG2 cells 20 µM 24 hours To investigate the effect of PDS on RNAPII-mediated long-range DNA contacts, results showed that PDS treatment significantly reduced DNA contacts involving G4 structure loci. Nucleic Acids Res. 2023 Sep 8;51(16):8434-8446
HeLa cells 100 µM 24 hours Assessed the effect of Pyridostatin on cell survival, showing increased sensitivity in USP50-depleted cells Nat Commun. 2024 Sep 16;15(1):8102
SV40-transformed human MRC5 fibroblasts 2 µM 24 hours Pyridostatin promoted growth arrest via inducing replication- and transcription-dependent DNA damage, leading to G2 phase cell cycle arrest. Nat Chem Biol. 2012 Feb 5;8(3):301-10
H1299+shBRCA2 DOX 10 µM 3 days Evaluate the activation of immune responses by Pyridostatin in BRCA2-deficient cells, showing increased IRF3 Ser386 phosphorylation EMBO Mol Med. 2022 Mar 7;14(3):e14501
Human telomere DNA 100 nM 30 minutes To evaluate the binding of Pyridostatin (PDS) to telomeric G-quadruplex and its inhibitory effect on DNA polymerase. Results showed that the dissociation constant Kd of PDS was 440 ±80 nM, and at 100 nM concentration, 18.7% of G-quadruplex was bound to PDS. Nucleic Acids Res. 2019 Apr 23;47(7):3295-3305
Human telomeric G-quadruplex 20 nM to 2 µM 30 seconds To determine the dissociation constant of PDS with G-quadruplex, results showed Kd of 490±80 nM Nat Chem. 2011 Aug 28;3(10):782-7
Human telomeric G-quadruplex 0.5 µM 30 seconds To evaluate the effect of PDS on the mechanical stability of G-quadruplex, results showed increased mechanical stability of PDS-bound G-quadruplex Nat Chem. 2011 Aug 28;3(10):782-7
HEK293T cells 2 µM or 10 µM 4 days To study the effect of PDS on DNA damage and cell cycle in RAD51-deficient cells Mol Cell. 2016 Feb 4;61(3):449-460
HepG2 cells 20 µM 48 hours To investigate the effect of PDS on HsACBP transcription, results showed that PDS significantly inhibited HsACBP transcription Nucleic Acids Res. 2022 Jul 8;50(12):6953-6967
MDA-MB-231 breast cancer cell line 2 µM 48 hours Pyridostatin significantly reduced SRC-dependent cellular motility. Nat Chem Biol. 2012 Feb 5;8(3):301-10
DLD1 cells 2 µM 48 hours To study the DNA damage response and cell cycle effects of PDS in BRCA2-deficient cells Mol Cell. 2016 Feb 4;61(3):449-460
Various cancer cell lines 2 µM 72 hours Pyridostatin inhibited cell proliferation and induced apoptosis in some cells. Nat Chem Biol. 2012 Feb 5;8(3):301-10
HT1080 fibrosarcoma cells 0.89 µM (GI50) 72 hours Evaluate the growth inhibition effect of PDS family ligands, PDSI showed the strongest growth inhibition J Am Chem Soc. 2013 Jul 3;135(26):9640-3

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Silkworm (Bombyx mori) Fifth instar larvae Injection 2, 4 or 6 μl of 15 mM Single injection, observed at 12, 24 and 36 hours post-injection To investigate the effect of PDS on larval development and lipid metabolism, results showed that PDS treatment led to reductions in fat body mass, body size and weight, and growth and metamorphic rates Nucleic Acids Res. 2022 Jul 8;50(12):6953-6967
CB17-SCID mice DLD1 BRCA2−/− xenograft tumours Intravenous injection 7.5 mg/kg/day Five consecutive days, followed by 2-day break and five more days of treatment Evaluate the inhibitory effect of Pyridostatin on BRCA2-deficient tumours, showing significant suppression of tumour growth EMBO Mol Med. 2022 Mar 7;14(3):e14501

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.68mL

0.34mL

0.17mL

8.38mL

1.68mL

0.84mL

16.76mL

3.35mL

1.68mL

References

 

Historical Records

Categories